Page last updated: 2024-11-01

ofloxacin and Lung Diseases

ofloxacin has been researched along with Lung Diseases in 19 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Lung Diseases: Pathological processes involving any part of the LUNG.

Research Excerpts

ExcerptRelevanceReference
"Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml."5.36In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010)
"Imipenem, levofloxacin or saline were administered to rats with caerulein induced pancreatitis."3.73Effects of selected antibiotics on pancreatitis induced liver and pulmonary injury. ( Coker, A; Coker, C; Erkan, N; Onek, T; Sağol, O; Zeytunlu, M, 2005)
"Ofloxacin was used in the treatment of 124 patients with bronchopulmonary diseases, the diseases of the biliary system and other infectious inflammatory diseases of the internal organs."2.68[Clinico-pharmacologic aspects of the use of ofloxacin]. ( Belitskaia, RA; Dubova, MN; Krasavina, MIu; Kukes, VG; Posrednikova, TA, 1996)
"Levofloxacin was the most potent antibiotic against all cystic fibrosis isolates tested, with MIC(90)s ranging from 8 to 32 microg/ml."1.36In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. ( Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O, 2010)
" The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection."1.35Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. ( Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009)
"Actinomycosis is a chronic suppurative bacterial infection characterized by multiple abscesses, fistulous pathways, and fibrosis involving the face, neck, chest, and abdomen."1.35Treatment of pulmonary actinomycosis with levofloxacin. ( Amado, J; Carvalho, A; Ferreira, Dde F; Neves, S; Nogueira, R; Taveira, N, 2008)
"We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung."1.28Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991)
"Pulmonary nocardiosis is a rare disease."1.28[A case of pulmonary nocardiosis associated with middle lobe atelectasis]. ( Katoh, O; Kuroki, S; Nagasawa, Z; Nakanishi, Y; Yamada, H; Yamaguchi, M, 1990)
"A 58-year-old man with pulmonary disease due to Mycobacterium fortuitum was treated successfully with ofloxacin (0."1.27Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. ( Ichiyama, S; Tsukamura, M, 1987)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19903 (15.79)18.7374
1990's7 (36.84)18.2507
2000's7 (36.84)29.6817
2010's2 (10.53)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sabet, M1
Miller, CE1
Nolan, TG1
Senekeo-Effenberger, K1
Dudley, MN2
Griffith, DC2
King, P1
Lomovskaya, O1
Burns, JL1
Fernández-Olmos, A1
García-Castillo, M1
Maiz, L1
Lamas, A1
Baquero, F1
Cantón, R1
Moretti, F1
Quiros-Roldan, E1
Casari, S1
Viale, P1
Chiodera, A1
Carosi, G1
Watson, AM1
Boyce, TG1
Wylam, ME1
Onek, T1
Erkan, N1
Zeytunlu, M1
Sağol, O1
Coker, C1
Coker, A1
Shitrit, D1
Baum, GL1
Priess, R1
Lavy, A1
Shitrit, AB1
Raz, M1
Shlomi, D1
Daniele, B1
Kramer, MR1
Ferreira, Dde F1
Amado, J1
Neves, S1
Taveira, N1
Carvalho, A1
Nogueira, R1
Fukuoka, Y1
Ikeda, Y1
Yamashiro, Y1
Takahata, M1
Todo, Y1
Narita, H1
Kukes, VG1
Belitskaia, RA1
Dubova, MN1
Krasavina, MIu1
Posrednikova, TA1
Weber, C1
Maas, R1
Steiner, P1
Kramer, J1
Bumann, D1
Zander, AR1
Bücheler, E1
Schreiber, J1
Burkhardt, U1
Rüsch-Gerdes, S1
Amthor, M1
Richter, E1
Zugehör, M1
Rosahl, W1
Ernst, M1
Marcos Sánchez, F1
Aparicio Martínez, JC1
Celdrán Gil, J1
Durán Pérez-Navarro, A1
Vallée, E1
Azoulay-Dupuis, E1
Pocidalo, JJ1
Bergogne-Bérézin, E1
Yamaoka, M1
Fukuchi, Y1
Yokouchi, M1
Teramoto, N1
Nagase, T1
Ishida, K1
Ohtomo, E1
Orimo, H1
Kuroki, S1
Yamada, H1
Katoh, O1
Nakanishi, Y1
Yamaguchi, M1
Nagasawa, Z1
Nakamura, S1
Minami, A1
Nakata, K1
Kurobe, N1
Kouno, K1
Sakaguchi, Y1
Kashimoto, S1
Yoshida, H1
Kojima, T1
Ohue, T1
Ichiyama, S1
Tsukamura, M1
Noel, F1
Couet, W1
Lefebvre, MA1
Akbaraly, JP1
Mignot, A1
Fourtillan, JB1

Trials

1 trial available for ofloxacin and Lung Diseases

ArticleYear
[Clinico-pharmacologic aspects of the use of ofloxacin].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:9

    Topics: Anti-Infective Agents; Antibody Formation; Bacterial Infections; Biliary Tract Diseases; Bronchial D

1996

Other Studies

18 other studies available for ofloxacin and Lung Diseases

ArticleYear
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9

    Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Ani

2009
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1

    Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, M

2010
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    International journal of antimicrobial agents, 2012, Volume: 40, Issue:2

    Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin;

2012
Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin.
    AIDS (London, England), 2002, Jul-05, Volume: 16, Issue:10

    Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Ant

2002
Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis.
    The Pediatric infectious disease journal, 2004, Volume: 23, Issue:1

    Topics: Child; Drug Therapy, Combination; Female; Follow-Up Studies; Hemosiderosis; Humans; Immunosuppressiv

2004
Effects of selected antibiotics on pancreatitis induced liver and pulmonary injury.
    Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2005, Volume: 11, Issue:1

    Topics: Acute Disease; Alanine Transaminase; Amylases; Animals; Anti-Bacterial Agents; Aspartate Aminotransf

2005
Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
    Chest, 2006, Volume: 129, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Ciprofloxacin; Clarithromycin; Cycloserine; Ethambutol; Ethionam

2006
Treatment of pulmonary actinomycosis with levofloxacin.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2008, Volume: 34, Issue:4

    Topics: Actinomycosis; Anti-Bacterial Agents; Diagnosis, Differential; Female; Humans; Levofloxacin; Lung Di

2008
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:3

    Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases

1993
[Importance of digital thoracic radiography in the diagnosis of pulmonary infiltrates in patients with bone marrow transplantation during aplasia].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1999, Volume: 171, Issue:4

    Topics: Adult; Anemia, Aplastic; Anti-Infective Agents; Antibiotic Prophylaxis; Antifungal Agents; Bone Marr

1999
[Non-tubercular mycobacterial infection of the lungs due to Mycobacterium smegmatis].
    Pneumologie (Stuttgart, Germany), 2001, Volume: 55, Issue:5

    Topics: Cardiopulmonary Resuscitation; CD4-Positive T-Lymphocytes; Clarithromycin; Drug Therapy, Combination

2001
[Ofloxacin in the treatment of lower respiratory tract infections in patients with chronic pulmonary diseases].
    Anales de medicina interna (Madrid, Spain : 1984), 1992, Volume: 9, Issue:8

    Topics: Chronic Disease; Humans; Lung Diseases; Ofloxacin; Respiratory Tract Infections

1992
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
    The Journal of antimicrobial chemotherapy, 1991, Volume: 28 Suppl C

    Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas

1991
Efficacy of oral administration of ofloxacin in lower respiratory tract infections in aged patients with chronic lung disease.
    Chemotherapy, 1991, Volume: 37 Suppl 1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Chronic Disease; Fe

1991
[A case of pulmonary nocardiosis associated with middle lobe atelectasis].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1990, Volume: 64, Issue:2

    Topics: Aged; Drug Combinations; Drug Therapy, Combination; Female; Gentamicins; Humans; Lung Diseases; Noca

1990
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
    Antimicrobial agents and chemotherapy, 1989, Volume: 33, Issue:8

    Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino

1989
Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum.
    Chest, 1987, Volume: 92, Issue:6

    Topics: Humans; Lung Diseases; Male; Middle Aged; Mycobacterium Infections; Ofloxacin; Oxazines; Radiography

1987
Diffusion of ofloxacin in human tissues.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987, Volume: 6, Issue:2 Suppl

    Topics: Administration, Oral; Adult; Female; Humans; Lung Diseases; Male; Middle Aged; Nephrectomy; Ofloxaci

1987